Proposal to modify the List of Permitted Supplemental Ingredients (vitamin B6)
Notice of Proposal – List of Permitted Supplemental Ingredients
Reference Number: PASF-2609
October 22, 2026
Summary
Vitamin B6 is currently authorized for use as a supplemental ingredient in supplemented foods sold in Canada. Following the publication of an updated scientific opinion on the tolerable upper intake levelFootnote 1 (UL) for vitamin B6 by the European Food Safety Authority Panel on Nutrition, Novel Foods and Food Allergens (EFSA NDA Panel)Footnote 2 and new relevant scientific evidence relating to vitamin B6 supplementation and peripheral neuropathy, Health Canada is proposing to:
- lower the maximum amount of vitamin B6 in caffeinated energy drinks (CEDs) from 11 mg to 10 mg per serving of stated size;
- add a threshold level of 2 mg per serving, above which a cautionary statement would be required on the label of CEDs, where none exist currently for vitamin B6
- lower the maximum amount of vitamin B6 in supplemented foods other than CEDs from 38 mg to 10 mg per serving of stated size; and
- lower the threshold levels above which cautionary statements are required on the label of supplemented foods other than CEDs, from 7 mg to 2 mg per serving.
You can submit comments on this proposal until January 20, 2027.
Background
Supplemented foods, including supplemental ingredients, are regulated in Canada under Part B of the Food and Drug Regulations (FDR).
Permitted supplemented food categories, as well as permitted supplemental ingredients along with their conditions of use, are set out in the List of Permitted Supplemented Food Categories and List of Permitted Supplemental Ingredients, respectively, which are incorporated by reference into the FDR.
A person, company or organization (referred to as the petitioner) may ask Health Canada to authorize the following by filing a pre-market submission:
- a new supplemental ingredient;
- a modification to the conditions of use for an already approved supplemental ingredient; or
- a modification to the permitted supplemented food categories.
Health Canada uses this pre-market approval process to determine whether the scientific data support the safety of the proposed change to the relevant lists. Ongoing monitoring by the Food and Nutrition Directorate may also prompt modifications to the lists based on emerging health risks, new scientific data, or outcomes of health risk assessments.
The Food and Nutrition Directorate stays up to date on the latest developments in nutrition, healthy eating and food safety and makes changes as needed to ensure that Health Canada's polices and regulations reflect the best available evidence supporting the nutritional quality and safety of foods for people in Canada.
Current Status
Vitamin B6 is permitted as a supplemental ingredient in foods belonging to the category listed in item 1 of the List of Permitted Supplemented Food Categories (i.e., carbonated or non-carbonated water-based beverages) that contain added caffeine and a total amount of caffeine from all sources of more than 150 p.p.m. (also known as caffeinated energy drinks (CEDs)). In CEDs, vitamin B6 is permitted at a maximum amount of 11 mg per serving, with no additional conditions of use specific to the vitamin. However, additional conditions of use, such as the required cautionary statement “Not recommended for those under 14 years old, pregnant or breastfeeding women or individuals sensitive to caffeine”, apply to these products due to the presence of caffeine as a supplemental ingredient.
Vitamin B6 is also permitted in foods belonging to a category listed in the List of Permitted Supplemented Food Categories, excluding CEDs (referred to herein as “supplemented foods other than CEDs”), at a maximum amount of 38 mg per serving. In these products, cautionary statements are required when the amount of vitamin B6 exceeds 7 mg per serving.
Health Canada established these conditions of use based on the tolerable upper intake levels (ULs) set by the National Academies of Sciences, Engineering and Medicine (NASEM) in 1998Footnote 3.
Issue
In spring 2023, the European Food Safety Authority (EFSA) Panel on Nutrition, Novel Foods and Food Allergens published an updated opinion on the UL for vitamin B6Footnote 2. EFSA’s updated ULs are substantially lower than those ULs set by NASEM in 1998 (e.g., 12 mg/day compared to 100 mg/day for adults).
In light of these newer and lower ULs, Health Canada’s Food and Nutrition Directorate initiated an evaluation to determine whether revised conditions of use for vitamin B6 in supplemented foods should be proposed.
Since this review of vitamin B6 in supplemented foods began, Health Canada’s Marketed Health Products Directorate (MHPD) also finalized an assessment on the association between vitamin B6-containing health products and peripheral neuropathy. Recommendations made as part of MHPD’s assessment included updating the monograph for vitamin B6-containing natural health products (NHP) to include a risk statement regarding peripheral neuropathy and advice to stop taking vitamin B6-containing products and consult a healthcare professional if symptoms of peripheral neuropathy occur. This statement will apply to all NHPs in Canada which contain vitamin B6 at a daily dose of 10 mg or above.
Rationale
In addition to EFSA’s scientific opinion, the Food and Nutrition Directorate considered control trials and case reports from the scientific literature, as well as information available in the Canada Vigilance Adverse Reaction Online Database.
There was some evidence of peripheral neuropathy with doses below 100 mg/day (NASEM’s UL), and below 50 mg (the reference point identified by EFSA for establishing their UL). However, due to the poor quality and incomplete nature of the reported data (e.g., lacking information on dose or duration), as well as the prevalence of concomitant medications, supplements, or medical conditions, the Food and Nutrition Directorate was not able to draw specific conclusions about the relationship between dose or duration of vitamin B6 consumption and peripheral neuropathy.
As part of this evaluation, the Food and Nutrition Directorate also considered MHPD’s assessment on the association between vitamin B6-containing health products and peripheral neuropathy. MHPD had also reviewed adverse reaction reports in the Canada Vigilance database, the scientific literature, as well as information from international pharmacovigilance groups and provided by foreign regulatory agencies. MHPD’s assessment identified a possible link between vitamin B6-containing NHPs and the risk of peripheral neuropathy, when the daily dose is 10 mg vitamin B6 or higher. Sufficient evidence to establish a link between vitamin B6-containing prescription drugs and the risk of peripheral neuropathy was not identified. As a result, NHPs providing a daily dose of 10 mg or more of vitamin B6 will require labelling to include a risk statement regarding peripheral neuropathy and what to do if symptoms occur. This threshold level aligns with EFSA’s recommendation to lower the UL to 12 mg/day, as well as with the threshold level established by Australia’s Therapeutic Goods Administration (TGA) for a similar warning statement on listed medicinesFootnote 4.
Considering the above, it is proposed that the current maximum amounts for all supplemented foods including CEDs be lowered to 10 mg/day, which is a level at which cautionary labelling regarding peripheral neuropathy is required for non-prescription health products in Canada and Australia.
Proposed threshold levels for cautionary statements on supplemented foods other than CEDs were established by dividing the maximum permitted level by five and rounding down, based on market research indicating that a subset of consumers may consume up to five servings in a single day. This results in a trigger of 2 mg per serving for cautionary statements, including limits on daily intake, avoidance of concurrent use with other supplements and supplemented foods, and an age-based restriction aligned with the lowest threshold to ensure younger populations can safely consume products without having to rely on understanding label information.
For CEDs, the absence of labelling triggered by vitamin B6, combined with the potential for multiple servings per day, could lead to intakes approaching levels at which adverse effects have been observed (e.g., up to 50 mg/day). Introducing a maximum number of servings statement at the 2 mg threshold helps mitigate this risk while avoiding a significant number of reformulations, particularly given that most CEDs already recommend limited daily consumption. Additional cautionary statements are not proposed where existing labelling requirements for other ingredients (e.g., caffeine) or related products (e.g., natural health products) are considered sufficient to address overlapping risks.
Proposed modification to the list
In light of the Food and Nutrition Directorate’s conclusion that the available safety information supports revised conditions of use for vitamin B6 as a supplemental ingredient, Health Canada proposes to modify the maximum permitted amounts for vitamin B6 and the threshold levels above which a cautionary statement is required on the label.
Specifically, Health Canada proposes to lower the threshold above which cautionary statements would be required on the label for supplemented foods other than CEDs from 7 mg to 2 mg per serving and to also require a threshold of 2 mg per serving for CEDs for such statements, where none previously applied, and to set the maximum amount at 10 mg per serving for all supplemented foods including CEDs by modifying the List of Permitted Supplemental Ingredients, as shown in Table 1 (in bold font to illustrate the change).
| Supplemental Ingredient | Conditions of Use | ||||
|---|---|---|---|---|---|
| Item No. | Column 1Footnote i Description |
Column 2 Permitted in |
Column 3Footnote ii Maximum Amounts and Units Per Serving of Stated Size |
Column 4Footnote iiiFootnote iv Cautionary Statements Required on the Label |
Column 5 Other |
| Part I: Vitamins | |||||
9 |
Vitamin B6 |
(1) Foods belonging to a category listed in the List of Permitted Supplemented Food Categories, excluding foods belonging to the category listed in item 1 that contain added caffeine and a total amount of caffeine from all sources of more than 150 p.p.m. |
(1) 10 mg |
(1) If the amount of vitamin B6 declared on the label is more than 2 mg per serving, the following cautionary statements are required:
|
(1) None specified |
(2) Foods belonging to the category listed in item 1 of the List of Permitted Supplemented Food Categories that contain added caffeine and a total amount of caffeine from all sources of more than 150 p.p.m. |
(2) 10 mg |
(2) If the amount of vitamin B6 declared on the label is more than 2 mg per serving, the following cautionary statement is required: |
(2) None specified |
||
Other relevant information
Labelling and reformulation considerations
The modifications to the threshold levels in items (1) and (2) of Column 4 of the table shown above represent a new labelling requirement for the use of vitamin B6 as a supplemental ingredient in foods set out in Column 2. In addition, some supplemented foods currently on the market may need to be reformulated to respect the modifications to the maximum amounts in items (1) and (2) in Column 3.
Implementation and enforcement
Modifications to the List of Permitted Supplemental Ingredients will come into force on the day they are published on Health Canada’s website. However, given that the proposed changes related to the maximum amounts, and threshold levels above which cautionary statements are required, fall within the scope of the joint Health Canada-Canadian Food Inspection Agency Food Labelling Coordination policy, Health Canada is proposing to give industry until January 1, 2030 to implement the labelling change and reformulation (if required) for products affected by the modification to items (1) and (2).
You can consult the Notices of Proposal and Notices of Modification web page to stay informed of these modifications and to obtain details on the transition period once finalized, or you can in register for Health Canada's Consultation and Stakeholder Information Management System to be automatically notified when they are issued.
The Canadian Food Inspection Agency is responsible for the enforcement of the Food and Drugs Act and its associated regulations with respect to foods.
Consultation
The consultation on the proposed modification to the List of Permitted Supplemental Ingredients (shown in Table 1) is open for 90 days from the date of publication of this notice.
You can submit your comments on this proposal by email until January 20, 2027 at food.ibr-ipr.aliments@hc-sc.gc.ca. Please use the words "vitamin B6 (PASF-2609)" in the subject line of your email.
The results of the consultation will be communicated in a notice of modification published at the same time the List of Permitted Supplemental Ingredients is modified if the proposal moves forward.
Useful links
Health Canada:
- Caffeinated energy drinks
- Supplemented Foods: Overview
- Guidance Document: Supplemented Foods Regulations
- Guidance document: Pre-market submission process for supplemented foods
Notes
- Footnote 1
-
The UL is the highest average daily nutrient intake level likely to pose no risk of adverse health effects to almost all individuals in a given life-stage and gender group.
- Footnote 2
-
EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), D. Turck, T. Bohn, et. al., “Scientific opinion on the tolerable upper intake level for vitamin B6,” EFSA Journal 21, no.5 (2023): 8006, 110 pp. https://efsa.onlinelibrary.wiley.com/doi/epdf/10.2903/j.efsa.2023.8006
- Footnote 3
-
National Academies of Sciences Engineering and Medicine (NASEM), formerly the Institute of Medicine (IOM), Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. (Washington, DC: The National Academies Press, 1998). https://doi.org/10.17226/6015
- Footnote 4
-
Therapeutic Goods Administration. 2021. Proposed changes to requirements for listed medicine ingredients: Annual low-negligible risk changes. Final Decisions. 2021-2022. https://consultations.tga.gov.au/medicines-regulation-division/low-neg-risk-2021-2022/user_uploads/low-negligible-risk-annual-consultation-2021-2022---final-decisions.pdf